M47 AI Company No limits are set. The Startup Born in Barcelona specialized in artificial intelligence (AI) is exploring new growth opportunities in sectors such as health, Pharmalegal and great consumption. All this under a 30% income growth forecasts this year compared to the preceding year to exceed 13 million euros.
The founder and CEO of the company, Enric Planadetails in conversation with electionomista.es That the firm also aspires to increase template, exceeding 200 employees, with a special approach to the incorporation of technical profiles related to the (AI and AI engineers Machine Learning) and also multidisciplinary programmers (Full-Stack).
According to Plana, the M47 AI Company strategy is based on three axes: the scalability of its artificial intelligence solutions through productivization so that they can be implemented agile in different industries; a strong international presence through 10 markets (and exploring opportunities in America and Asia); and continuous innovation.
100% own capital
“In the long term, our goal is to consolidate as a global reference in applied, maintaining our independence and betting on sustainable development,” says the manager. Capital is 100% own and, for now, the company does not contemplate the option of a financing round. Plana, who created the firm together with David Sánchezthe current technology director (CTO) says that this position has allowed the Catalan startup to grow more flexibly, “without being subject to a strictly defined plan.”
“This has given us the freedom to explore different areas, pivot when it has been necessary and adjust our projects according to the needs of the market and our learning. Thanks to this independence, we have been able to innovate with greater agility and make strategic decisions without external pressures, which has been key to the growth and consolidation of M47 AI Company,” he says.
Open to other options
However, Flat does not close in band to any type of operation and even sees the leap into the healing as an “interesting option” to finance growth and reinforce the image of the company’s solidity. Thus indicates that BME Scaleup, the market for growing companies, is an option that would provide visibility and prestige, as well as access to capital. “We will assess the BME Scaleup in the future if it serves us as an instrument to reach our objectives1,” he says.
#M47 #Company #plans #raise #income #enter #sectors #legal #Pharma
